His focus is on medical devices and biotechnology. He is a member of a NVCA CFO Task Force and has served on the West Coast Chapter Board of Directors of the Private Equity CFO Association (PECFOA). Matt is a Certified Public Accountant and is a member of the California State Board of Accountants.
![delphi stock delphi stock](https://st.focusedcollection.com/14026668/i/1800/focused_458914968-stock-photo-greece-delphi-temple-apollo.jpg)
providing audit, tax and business advisory services to private companies, real estate investment partnerships, and not-for-profit organizations. Prior to Bluecurve, he spent six years in public accounting with former Arthur Andersen managers Schorno, Murray & Co. He held various reporting and operational duties until the company's acquisition by Red Hat, Inc.
DELPHI STOCK SOFTWARE
Prior to joining Delphi Ventures in 2000, Matt spent three years as Controller at Bluecurve, Inc., an enterprise performance management software startup. He also leads the firm's administrative and operational efforts including investor relations, human resources, information technology, legal affairs and portfolio company assistance. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.Īs Chief Financial Officer, Matt has primary responsibility for Delphi's accounting and reporting. She serves as Vice-Chair of the San Francisco Conservatory of Music’s Board of Trustees.ĭeepa received her Ph.D. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies that raised over $9 billion. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P.
![delphi stock delphi stock](https://c8.alamy.com/comp/BJG89M/the-roman-market-the-agora-at-delphi-greece-below-mount-parnassus-BJG89M.jpg)
She also led the investments in Cardeas Pharma, KAI Pharmaceuticals (acquired by Amgen), and a PIPE investment in Seattle Genetics (Nasdaq:SGEN).ĭeepa joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice which focuses on drug discovery and development platform technologies that have resulted in multiple novel drugs, including six that are commercially marketed. She currently serves on the boards of Alder Biopharmaceuticals (Nasdaq:ALDR), Calithera Biosciences (Nasdaq: CALA), ForSight:Vision5, Karyopharm Therapeutics (Nasdaq:KPTI) and Oncomed Pharmaceuticals (Nasdaq:OMED).ĭeepa previously served on the boards of Salmedix (acquired by Cephalon), Ilypsa (acquired by Amgen), Proteolix (acquired by Amgen), PTC Therapeutics (Nasdaq:PTCT) and Relypsa(Nasdaq:RYLP).
![delphi stock delphi stock](https://cdn.w600.comps.canstockphoto.com/archaeological-site-of-delphi-in-greece-stock-photos_csp73935030.jpg)
Deepa is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities.